Peter Hersh

Last updated

Peter S. Hersh is an American ophthalmologist, researcher, and specialist in LASIK eye surgery, keratoconus, and diseases of the cornea. He co-authored the article in the journal Ophthalmology that presented the results of the study that led to the first approval by the U.S. Food and Drug Administration (FDA) of the excimer laser for the correction of nearsightedness in the United States. Hersh was also medical monitor of the study that led to approval of corneal collagen crosslinking for the treatment of keratoconus. He was the originator, in 2015, of CTAK (corneal tissue addition keratoplasty) for keratoconus, patent holder, and co-developer. [1]

Contents

Life and career

Hersh grew up in Maplewood, New Jersey, and graduated from Columbia High School.

Hersh graduated from Princeton University with an A.B. in biochemistry, where he was awarded the Senior Thesis prize for his work on messenger RNA.[ citation needed ] He received his medical degree (M.D.) from Johns Hopkins University and completed his residency training at Harvard Medical School where he was Chief Resident. He also completed a Fellowship in Cornea and External Disease at Harvard. Afterwards, Hersh remained on the full-time faculty at Harvard.

In 1995 he founded the Cornea and Laser Eye Institute (CLEI) – Hersh Vision Group in New Jersey and serves as its director. [2] He also founded the CLEI Center for Keratoconus in 2001, dedicated to clinical care and research in the corneal disorder, keratoconus. He is a clinical professor at the Rutgers - New Jersey Medical School Institute of Ophthalmology and Visual Science and director of the Institute's Cornea and Refractive Surgery Division and is a Visiting Research Collaborator at Princeton University in the Department of Mechanical and Aerospace Engineering. [3] [4] [5] He is also the Chief Team Ophthalmologist for the NY Jets. [6]

Hersh is a member of the American Ophthalmological Society [7] and has been awarded the Senior Honor Award from the American Academy of Ophthalmology. [8] He is also a past recipient of the Teacher of the Year Award from the Harvard Medical School Residency in Ophthalmology.[ citation needed ]

Research

Hersh's research is focused on developing new techniques and technologies in refractive and corneal surgery, most particularly for the corneal disorder, keratoconus. He is the originator of CTAK (corneal tissue addition keratoplasty) for keratoconus, patent holder (US11759308B2, US11406531B1), and co-developer. [1] His clinical interests are devoted to treatment of keratoconus, LASIK, femtosecond laser uses in LASIK and other corneal surgeries, LASEK/Photorefractive keratectomy, CK (conductive keratoplasty), and corneal inlays (Intacs) for keratoconus. [9] He authored or co-authored more than 100 research articles and abstracts on these subjects and has written or co-written four textbooks.

Hersh participated in nationwide clinical trials that led to the U.S. FDA's approval of the excimer laser system for the correction of nearsightedness and for the treatment of a variety of corneal diseases in the United States and co-authored the article that presented the results of the study. [10] [11]

Hersh is co-author of a patent regarding the use of short pulsed lasers for corneal surgery (#11/843,498) [12] and is the inventor of a number of surgical instruments used in corneal surgery, such as the Hersh Intralase Flap Spatula [13] and a complete instrument set for the CTAK procedure.

Hersh was one of two investigators to present the conductive keratoplasty (CK) procedure to the FDA device panel. [14] This led to FDA approval of this procedure in 2002. [15] He expanded on these efforts in his thesis for admission to the American Ophthalmological Society entitled "Optics of Conductive Keratoplasty: Implications for Presbyopia Management". [16] He has also devised new applications of this technique to treat optical irregularities of the cornea.

Hersh has done extensive work on corneal collagen cross-linking (CXL), a procedure for decreasing the progression of keratoconus and corneal ectatic disorders, [17] and he has published numerous articles in ophthalmology medical journals analyzing the results of the use of this procedure for keratoconus and ectasia. [18] [19] [20] [21] [22] [23] [24] As of 2013, he was the U.S. medical monitor for the medical device and pharmaceutical company Avedro, which has developed a new technique of cross-linking to manage keratoconus. [25] [26] Hersh was one of 7 principal investigators involved in the Avedro clinical trials for patients with keratoconus [27]

Publications

Books

Articles

References

  1. 1 2 "Hersh peter sPatents". PatentGuru. Retrieved 2024-04-23.
  2. ↑ Cornea and Laser Eye Institute-Hersh Vision Group. Peter S. Hersh, M.D.. Retrieved 17 May 2013.
  3. ↑ "Peter S. Hersh, M.D." University of Medicine and Dentistry of New Jersey.
  4. ↑ "Professional Staff". Princeton University.
  5. ↑ Parker, Hilary. "Frontiers of health: Sight for sore eyes". Princeton University. Retrieved 10 April 2013.
  6. ↑ "Official Site of the New York Jets". www.newyorkjets.com. Retrieved 2024-04-24.
  7. ↑ "American Ophthalmological Society" . Retrieved July 27, 2012.
  8. ↑ "Official Site of the New York Jets". www.newyorkjets.com. Retrieved 2024-04-23.
  9. ↑ Charters, Linda. "Keratoconus Approach is promising". Ophthalmology Times. Retrieved April 1, 2010.
  10. ↑ Hersh, Peter; Stulting D; Steinert RF; Waring GO; Thompson K; Doney K; O'Connell M. (1997). "Results of phase III excimer laser photorefractive keratectomy for myopia". Ophthalmology. 104 (10): 1535–1553. doi:10.1016/s0161-6420(97)30073-6. PMID   9331190.
  11. ↑ Maloney, R.K. "A multicenter trial of photorefractive keratectomy for residual myopia after previous ocular surgery" . Retrieved 16 April 2013.
  12. ↑ "Method and device for cornea reshaping by intrastromal tissue removal". The United States Patent and Trademark Office. Archived from the original on 2013-06-26. Retrieved 2013-04-17.
  13. ↑ "Hersh Intralase Flap Spatula". Katena.
  14. ↑ Thornton, Sara. "Summary minutes of the ophthalmic devices panel meeting" (PDF). www.fda.gov. Archived from the original (PDF) on April 27, 2003. Retrieved November 30, 2001.
  15. ↑ "ViewPoint™ CK System - P010018". Food and Drug Administration.[ dead link ]
  16. ↑ Hersh, Peter (2005). "Optics of Conductive Keratoplasty: Implications for Presbyopia Management" (PDF). Transactions of the American Ophthalmological Society. 103: 412–56. PMC   1447583 . PMID   17057812. Archived from the original (PDF) on 2013-09-26. Retrieved 2013-04-10.
  17. ↑ Preston, Courtney. "Collagen cross-linking shows promise for slowing keratoconus, ectasia". Ocular Surgery News U.S. Edition. Retrieved April 25, 2011.
  18. ↑ Greenstein, Steven; Fry KL; Bhatt J; Hersh PS (2010). "Natural history of corneal haze after collagen crosslinking for keratoconus and corneal ectasia: A Scheimpflug and biomicroscopic analysis". Journal of Cataract and Refractive Surgery. 36 (12): 2105–2114. doi:10.1016/j.jcrs.2010.06.067. PMID   21111314. S2CID   1243528.
  19. ↑ Hersh, Peter; Greenstein SA; Fry KL (2011). "Corneal collagen crosslinking for keratoconus and corneal ectasia: One year results". Journal of Cataract and Refractive Surgery. 37 (1): 149–160. doi:10.1016/j.jcrs.2010.07.030. PMID   21183110. S2CID   1495812.
  20. ↑ Greenstein, Steven; Shah VP; Fry KL; Hersh PS (2011). "Corneal thickness changes after corneal collagen crosslinking for keratoconus and corneal ectasia: One-year results". Journal of Cataract and Refractive Surgery. 37 (4): 691–700. doi:10.1016/j.jcrs.2010.10.052. PMID   21420594. S2CID   45397974.
  21. ↑ Greenstein, Steven; Fry KL; Hersh PS (2011). "Corneal topography indices after corneal collagen crosslinking for keratoconus and corneal ectasia: One-year results". Journal of Cataract and Refractive Surgery. 37 (7): 1282–1290. doi:10.1016/j.jcrs.2011.01.029. PMID   21700105. S2CID   22968419.
  22. ↑ Greenstein, Steven; Fry KL; Hersh PS (2012). "In Vivo Biomechanical Changes After Corneal Collagen Cross-linking for Keratoconus and Corneal Ectasia: 1-Year Analysis of a Randomized, Controlled, Clinical Trial". Cornea. 31 (1): 21–25. doi:10.1097/ico.0b013e31821eea66. PMID   21993470. S2CID   10149180.
  23. ↑ Greenstein, Steven; Fry KL; Hersh MJ Hersh PS (2012). "Higher-order aberrations after corneal collagen crosslinking for keratoconus and corneal ectasia". Journal of Cataract and Refractive Surgery. 38 (2): 292–302. doi:10.1016/j.jcrs.2011.08.041. PMID   22322165. S2CID   5812226.
  24. ↑ Brooks, N; Greenstein SA; Fry KL; Hersh PS (2012). "Patient subjective visual function after corneal collagen crosslinking for keratoconus and cornea ectasia". Journal of Cataract and Refractive Surgery. 38 (4): 615–619. doi:10.1016/j.jcrs.2011.11.029. PMID   22342006. S2CID   17421548.
  25. ↑ Avedro. Medical Advisory Board. Retrieved 17 May 2013.
  26. ↑ "LASIK Founder Files NDA for LASIK Injury-healing Drug". www.fdaweb.com. Retrieved March 9, 2012.
  27. ↑ U.S. National Institutes of Health (ClinicalTrials.gov). Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus. Retrieved 17 May 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.